Moderna Inc

NASDAQ:MRNA  
324.04
-7.84 (-2.36%)
4:55:50 PM EDT: $323.25 -0.79 (-0.24%)
Production Guidance

Moderna Provides Updates On Clinical Development And Production Of COVID-19 Vaccine Candidate

Published: 12/03/2020 22:58 GMT
Moderna Inc (MRNA) - Moderna Provides Updates on the Clinical Development and Production of Its Covid-19 Vaccine Candidate.
Moderna Inc - Company Expects to Have Between 100 Million and 125 Million Doses Available Globally in Q1 of 2021.
Moderna Inc - Expects to Have Between 100 Million and 125 Million Doses Available Globally in Q1 of 2021.
Moderna Inc - Reaffirms Expectation to Have 20 Million Doses Available in U.S. by End of 2020.
Moderna Inc - at Day 119, 3 Months Post-second 100 Μg Dose, Binding and Neutralizing Antibody Titers Remain High in All Participants in Trial.
Moderna Inc - Covid-19 Vaccine Candidate Trial Results Consistent Across All Age Groups (18-55, 56-70 and 71+).
Moderna Inc - Expects to Have 85-100 Million Doses Available in U.S. and 15-25 Million of Those Available Outside of U.S.moderna Inc - Expected Q1 Doses Are Inclusive Within 500 Million to Up to 1 Billion Doses That Company Expects to Manufacture Globally in 2021.
Moderna Inc - Interim Durability Data From Nih-led Phase 1 Study of Mrna-1273 Published As Letter to Editor in Nejm.